References
- Roberts HR, Ma AD. Overview of inherited hemorrhagic disorders. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice (5th Edition). Colman RW, Marder VJ, Clowes AW, Gerorge JN, Goldhaber SZ (Eds). Lippincott Williams & Wilkins, PA, USA, 877–885 (2006).
- Mann KG, Nesheim ME, Church WR, Haley PE, Krishnaswamy S. Surface dependent reactions of the vitamin K-dependent enzyme complexes. Blood 76(1), 1–16 (1990).
- Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 14(Suppl. 3), 10–18 (2008).
- Turecek PL, Varadi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia 10(Suppl. 2), 3–9 (2004).
- Hedner U, Ezban M. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis. Annu. Rev. Med. 59, 29–41 (2008).
- Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 15(1), 3–10 (2009).
- Schaub RG. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem. Pharmacol. 82(2), 91–98 (2011).
- Schlachterman A, Schuettrumpf J, Liu JH et al. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J. Thromb. Haemost. 3(12), 2730–2737 (2005).
- Butenas S, Orfeo T, Kalafatis M, Mann KG. Peptidomimetic inhibitors for activated protein C: implications for hemophilia management. J. Thromb. Haemost. 4(11), 2411–2416 (2006).
- Ton-That TT, Doron D, Pollard BS, Bacher J, Pollard HB. In vivo bypass of hemophilia A coagulation defect by factor XIIa implant. Nat. Biotechnol. 18(3), 289–295 (2000).
- Prasad S, Lillicrap D, Labelle A et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 111(2), 672–679 (2008).
- Waters EK, Genga RM, Schwartz MC et al. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 117(20), 5514–5522 (2011).
- Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br. J. Haematol. 69(4), 491–497 (1988).
- Toso R, Zhu H, Camire RM. The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly. J. Biol. Chem. 283(27), 18627–18635 (2008).
- Ivanciu L, Toso R, Margaritis P et al. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat. Biotechnol. 29(11), 1028–1033 (2011).
- Himmelspach M, Richter G, Muhr E et al. A fully recombinant partial prothrombin complex effectively bypasses fVIII in vitro and in vivo. Thromb. Haemost. 88(6), 1003–1011 (2002).
- Tomokiyo K, Nakatomi Y, Araki T et al. A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone. Vox Sang. 85(4), 290–299 (2003).
- Wolf DL, Lin PH, Hollenbach S et al. Procoagulant activity of reversibly acylated human factor Xa. Blood 86(11), 4153–4157 (1995).
- Louvain-Quintard VB, Bianchini EP, Calmel-Tareau C, Tagzirt M, Le Bonniec BF. Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas. J. Biol. Chem. 280(50), 41352–41359 (2005).
- Khan AM, James MNG. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Prot. Sci. 7(4), 815–836 (1998).
- Bunce MW, Toso R, Camire RM. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood 117(1), 290–298 (2011).